Stock comparison
Harmony Biosciences Holdings
Indivior Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
INDV
Indivior Pharmaceuticals
Market cap
$4.68B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | INDV | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 35D | HRMY |
| Benjamin Graham | 60C | 30F | HRMY |
| Philip Fisher | 75B | 44D | HRMY |
| Peter Lynch | 62C | 71B | INDV |
| Joel Greenblatt | 28F | 78B | INDV |
| Charlie Munger | 62C | 50D | HRMY |
| Terry Smith | 67B | 46D | HRMY |
Side-by-side metrics
| Metric | HRMY | INDV |
|---|---|---|
| Market cap | $1.75B | $4.68B |
| P/E (TTM) | 11.8x | 19.0x |
| EV/EBIT | 6.4x | 19.1x |
| ROIC (TTM) | 12.5% | 85.68% |
| Gross margin | 76.55% | 83.11% |
| Net margin | 16.2% | 19.44% |
| Revenue CAGR 5y | 29.85% | 11.87% |
| EPS CAGR 5y | 46.45% | 5.04% |
| Debt / Equity | 0.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EPS CAGR 5y46.45%vs 5.04%+89%
- EV/EBIT6.4xvs 19.1x+66%
- Revenue CAGR 5y29.85%vs 11.87%+60%
- P/E (TTM)11.8xvs 19.0x+38%
INDV leads on
- Debt / Equity-vs 0.2x+106%
- ROIC (TTM)85.68%vs 12.5%+85%
- Market cap$4.68Bvs $1.75B+63%
- Net margin19.44%vs 16.2%+17%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.